Global CDMO Flamma operates a global integrated network with FDA inspected cGMP sites in Italy and a U.S. facility in Malvern, PA, plus a fully owned site in Dalian, China, supported by a new cGMP plant as part of a $200M expansion. This suggests potential for multi-region manufacturing partnerships, supply chain diversification, and regional regulatory familiarity for global clients.

Full-Service Scope Offering from early stage process R&D to commercial production of APIs, starting materials, and advanced intermediates indicates opportunities to engage customers across the entire development lifecycle, especially those seeking a single partner to de-risk programs and streamline timing.

Growth & Recognition Recent awards for CDMO leadership and a track record of expansion, including leadership appointments in Italy and enhancements to Europe operations, signal a proven growth trajectory and proven reliability—appealing to risk-averse sponsors seeking trusted partners with scale.

Digital Modernization Implementation of centralized electronic lab notebook systems to improve data visibility across sites points to strong capabilities in data integrity, tech-enabled project tracking, and potential for accelerated timelines and compliant collaboration with clients.

High Potency & Compliance U.S. capabilities include early stage development, high potency APIs, and controlled substance handling, complemented by cross-border coordination with China. This opens doors for clients needing specialized, compliant handling and accelerated development pathways for complex or regulated programs.